Tango Therapeutics (TNGX) Stock: Why It Fell 17% on ESMO Data

Quick answer

Tango Therapeutics stock fell 17.6% to $23.01 at about 9:45am ET on Oct 23, 2026, from a $27.93 close, after the company showed updated pancreatic cancer data at the ESMO Congress and said a Phase 3 trial would start in the first half of 2027. The data were good but a little weaker than the June readout that sent the stock up 53%: vopimetostat plus Revolution Medicines' daraxonrasib produced a response rate of 82% in 22 patients, down from 92% in 12. Tango filed an 8-K at about 6:36am, and the stock had risen 26.7% in four sessions, from $22.04 on Oct 16, so the bar was high. The rest of biotech fell far less: the biotech ETF XBI was down 2.1% and Revolution Medicines 1.5%.

Our view: Bullish through November 10, 2026, a week after third-quarter results are expected on about Nov 3. The case against the stock is real: the response rate slipped from 92% to 82% as the sample nearly doubled, 40% of patients on the lower dose had a Grade 3 treatment-related adverse event, the higher dose had dose-limiting toxicities, the Phase 3 is months away, and a $400 million at-the-market program and a short float of 36% can pressure the price. The case for the stock carries more weight. An 82% response rate with 100% disease control and an 88% nine-month progression-free rate, in patients who all had prior treatment and were followed for a median of 7.1 months, is the same story as June with more patients. Tango has held its FDA discussions and laid out a Phase 3 design. The shares are now 26% below the $30.93 close on the day of the June data, and they fell about eight times as far as the group. A selloff this much larger than what changed at the company argues Bullish. We would move to Bearish if Tango says the Phase 3 start will slip past the first half of 2027 or that the FDA wants a different design, if the third-quarter 10-Q shows heavy use of the at-the-market program at prices near today's, or if new data at the 200 mg dose show Grade 4 or 5 events or dose-limiting toxicities. We would move to Neutral if the stock fully recovers the $27.93 close without new data. This is a view on direction over that window, not a recommendation to trade the stock.

Tango Therapeutics daily closing price from Sep 1 to Oct 23, 2026, with the $22.04 close on Oct 16, the $27.93 close before the data and the Oct 23 drop marked

Key takeaways

Tango Therapeutics fell 17.6% to $23.01 at about 9:45am ET on Oct 23, 2026, from a $27.93 close, after it reported an 82% response rate for vopimetostat plus daraxonrasib in pancreatic cancer and said a Phase 3 trial would start in the first half of 2027.
The data confirmed June but did not beat it: the response rate was 82% in 22 patients (18 responders), down from 92% in 12 patients (11 responders), and the stock had risen 26.7% in four sessions, from $22.04 on Oct 16 to $27.93, before the release.
The drop was far larger than the group's: the biotech ETF XBI fell 2.1%, Revolution Medicines fell 1.5% and Ideaya fell 2.3% at the same time.
At the lower dose, 40% of 25 patients had a Grade 3 treatment-related adverse event and none had Grade 4 or 5; at the higher dose, 2 of 4 patients had dose-limiting toxicities and the company called it not well tolerated.
Our view is Bullish through November 10, 2026: the price now sits below where it traded after the June data, the company holds $1.014 billion in cash and equivalents, and nothing in the release weakens the case for the Phase 3.

Table of contents

Oct 23, 2026: strong data, a lower response rate and a gap down
The data, in numbers
The bull case
The risks
What comes next

Oct 23, 2026: strong data, a lower response rate and a gap down

Tango released its data at about 6:30am ET and held a webcast for investors at 7:30am. In premarket trading the stock was $25.45, down 8.9%, RTTNews reported. It opened at $25.54 and fell to $23.61 within the first five minutes, bounced to $24.50 by about 9:40am, then slid again. At about 9:45am it was $23.01 on 2.65 million shares, and the low so far was $22.82. The day's high, $25.71, came at the open.

What pushed it down:

The response rate fell. In June, 11 of 12 patients responded to vopimetostat plus daraxonrasib, or 92%. The new data count 18 of 22 responders, or 82%, with a disease control rate of 100%. Eleven responses were confirmed and seven more were unconfirmed at the Aug 20 cutoff and later confirmed. On samples this small the gap is within chance, but it was the first thing the market could read.
Expectations had run ahead. From Oct 16 to Oct 22 the stock rose from $22.04 to $27.93, up 26.7%, and it gained 3.5% on Thursday alone. Commentary on Oct 20 already asked how much of the data was priced in.
Safety questions. At the lower dose level, 40% of 25 patients had a Grade 3 treatment-related adverse event. The most common events were stomatitis (48%), rash (44%) and diarrhea (28%), all Grade 1 or 2; none had Grade 4 or 5 events and none stopped treatment because of side effects. The higher dose level had three dose-limiting toxicities in two of four patients and was not well tolerated.
The pace is slow. The Phase 3 is not planned to start until the first half of 2027, so the next hard efficacy data are a long way off. Its dual primary endpoints are response rate and progression-free survival, with overall survival a key secondary endpoint, against standard chemotherapy.
No help from the zoldonrasib arm. The combination with Revolution's other drug, zoldonrasib, in pancreatic cancer with a KRAS G12D mutation showed a 54% response rate in 35 patients and a nine-month progression-free rate of 61%, close to June's 52%.

From the Oct 22 close, at about 9:45am:

Stock or fund	Oct 22 close	Oct 23, about 9:45am	Change
Tango Therapeutics (TNGX)	$27.93	$23.01	-17.6%
Kura Oncology (KURA)	$9.86	$9.42	-4.5%
Arvinas (ARVN)	$7.72	$7.47	-3.3%
Ideaya Biosciences (IDYA)	$36.12	$35.29	-2.3%
SPDR S&P Biotech ETF (XBI)	$151.64	$148.40	-2.1%
Syndax (SNDX)	$13.57	$13.32	-1.9%
Revolution Medicines (RVMD)	$187.69	$184.88	-1.5%
iShares Biotechnology ETF (IBB)	$209.54	$206.61	-1.4%
SPDR S&P 500 ETF (SPY)	$763.96	$760.49	-0.5%

Bar chart of declines from the Oct 22 close at about 9:45am ET on Oct 23: TNGX 17.6%, KURA 4.5%, ARVN 3.3%, IDYA 2.3%, XBI 2.1%, SNDX 1.9%, RVMD 1.5%, IBB 1.4%, SPY 0.5%

Biotech was soft, with XBI down 2.1%, but Tango fell about eight times as far. Revolution Medicines, whose drug is the partner in the combination, fell only 1.5%, so the market is not marking down the combination as a whole. It is repricing Tango's share of the upside after a run. For other biotech names that moved on data, see our pages on Biohaven and Rapport Therapeutics, and today's biggest stock moves.

At about 9:45am on Oct 23, RSI(14) stood at 47, the shares sat 3% below their 50-day average and 5% above their 200-day average, volume of 2.65 million shares ran 0.7 times its 20-day average of 3.8 million shares, and the stock was 33% below its 52-week high of $34.39.

The data, in numbers

Bar chart of objective response rates: daraxonrasib combination 92% in June and 82% in October, zoldonrasib combination 52% in June and 54% in October

The October update covers a data cutoff of Aug 20, 2026. Of 22 efficacy-evaluable pancreatic patients, 13 received the combination as third-line therapy. Median follow-up was 7.1 months, with a range of 3.3 to 12.5 months, and median progression-free survival was not yet reached. Tango also reported four of five patients responding in lung cancer at the lower dose. That group is too small to carry weight.

The June figures were 11 of 12 patients responding, nine responses confirmed, and a six-month progression-free rate of about 90%. The stock closed that day at $30.93, up 53% from $20.22.

The bull case

The tail of the curve. 88% of patients had not progressed at nine months. Principal investigator Alexander Spira said so despite heavy pretreatment, and Anna Berkenblit of PanCAN called the results worth rapid evaluation in a larger, randomized trial.
A defined path. The Phase 3 will randomize patients 1:1 to vopimetostat 200 mg plus daraxonrasib 100 mg or chemotherapy, in front-line MTAP-deleted disease. Tango will also discuss a second-line approval with regulators and keeps studying tumors without the MTAP deletion.
Cash. Tango held $1.014 billion at the end of June against a market value near $3.9 billion at today's price, and its second-quarter loss was $55.3 million. Our guide to estimating cash runway shows how to check a figure like that.
Valuation against targets. The average analyst target is $45.91 and the median is $40, with a high of $69 and a low of $24, so only the lowest target is near today's price.

The risks

Small samples. The October response rate rests on 22 patients, and 13 of them were third-line. A randomized trial can disappoint where a single-arm study did not; see our explainer on valuing a binary event.
Tolerability. Grade 3 events in 40% of patients at the lower dose are manageable in cancer care, but a longer treatment course in front-line patients may look different.
Dilution. On Aug 11 Tango filed to sell up to $400 million of stock at market prices through Leerink, replacing an earlier $100 million program of which about $64.4 million had been sold. At the assumed price of $27.07 that was 14.8 million shares on top of 168.4 million outstanding at June 30. Our explainer on dilution covers how this works.
Crowded positioning. The short float is 36%. A high short float can speed a rebound and a drop alike; see short interest and squeeze risk.
A partner's drug. The combination depends on daraxonrasib, which Tango does not own.

What comes next

ESMO, through Oct 27. The congress runs Oct 23 to 27 in Madrid, and analyst reactions and updated price targets should follow in the coming days.
Third-quarter results, expected around Nov 3. The report will show cash at Sept 30, spending, and any stock sold under the at-the-market program. Our guide to preparing for an earnings report explains what to check.
FDA feedback on the Phase 3 and a possible second-line filing. Dates have not been given. The difference between hard and soft catalysts matters here, since a filing date is hard and a plan to talk is soft.
The first half of 2027. The planned Phase 3 start. For the tools biotech investors use to follow these dates, see our list of FDA calendars and biotech catalyst trackers.

Frequently asked questions

Why is Tango Therapeutics stock down today?

Tango fell 17.6% to $23.01 at about 9:45am ET on Oct 23, 2026. It reported updated Phase 1/2 data at the ESMO Congress: an 82% response rate (18 of 22 patients) for vopimetostat plus daraxonrasib in second- and third-line pancreatic cancer, against 92% (11 of 12) in June. The stock had risen 26.7% over the previous four sessions.

What were the Tango Therapeutics ESMO results?

In 22 efficacy-evaluable patients, vopimetostat plus daraxonrasib produced a response rate of 82%, a disease control rate of 100% and a nine-month progression-free survival rate of 88%. Median progression-free survival had not been reached after a median follow-up of 7.1 months. The data cutoff was Aug 20, 2026.

What is vopimetostat?

Vopimetostat is Tango's oral PRMT5 inhibitor, aimed at tumors that have lost the MTAP gene. In this study it is given with daraxonrasib, a RAS(ON) inhibitor from Revolution Medicines. It remains investigational and has not been approved for any use.

When does Tango's Phase 3 trial start?

Tango plans to start a global, randomized, registrational Phase 3 in front-line MTAP-deleted pancreatic cancer in the first half of 2027, after discussions with the FDA. Patients would receive vopimetostat 200 mg plus daraxonrasib 100 mg daily or standard chemotherapy. The dual primary endpoints are response rate and progression-free survival.

Why did Tango stock jump 53% in June?

On June 8, 2026, Tango reported that 11 of 12 evaluable pancreatic cancer patients responded to vopimetostat plus daraxonrasib, a 92% response rate. The stock closed at $30.93, up 53% from $20.22. Oct 23's update added patients and found a lower rate.

How much cash does Tango Therapeutics have?

Tango reported $1.014 billion of cash, cash equivalents and marketable securities. Its second-quarter net loss was $55.3 million, or $0.37 a share. In August it set up a program to sell up to $400 million of stock at market prices, so the share count can rise.

When does Tango Therapeutics report earnings?

Third-quarter results are expected around Nov 3, 2026, but the company had not confirmed a date as of Oct 23. The 10-Q will show how much stock it sold under its at-the-market program and its cash at Sept 30.

Sources

Article details

By James Whitfield, Head of Equity Research, Dombey Capital

Published October 23, 2026 · 7 min read · Event-Driven Investing